SCHEMBL22494322

SCHEMBL22494322

CNc1nc(N)c2c(I)nn(C(C)C)c2n1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTK6 Q13882 4/20 0.34
MTOR P42345 4/20 0.32
RICTOR Q6R327 3/20 0.32
RPTOR Q8N122 3/20 0.32
MAPKAP1 Q9BPZ7 3/20 0.32
MLST8 Q9BVC4 3/20 0.32
PIK3CA P42336 3/20 0.32
F2R P25116 1/20 0.31
SRC P12931 3/20 0.31
ABL1 P00519 2/20 0.31
HCK P08631 2/20 0.31
PIK3CD O00329 1/20 0.31
EGFR P00533 1/20 0.31
KDR P35968 1/20 0.31
PIK3CB P42338 1/20 0.31
PIK3CG P48736 1/20 0.31
EPHB4 P54760 1/20 0.31
PRKDC P78527 1/20 0.31
PI4KB Q9UBF8 1/20 0.31
CDK1 P06493 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22494314 0.78 CDK1 (0.35) MTORRICTORRPTORMAPKAP1MLST8
SCHEMBL868687 0.70 ABL1 (0.58) MTORPIK3CASRCABL1HCK
SCHEMBL12920888 0.70 KMT2A (0.43) MTORPIK3CAPIK3CDPIK3CBPIK3CG
SCHEMBL22494449 0.69 MTOR (0.47) MTORRICTORRPTORMAPKAP1MLST8
SCHEMBL31403518 0.69 MTOR (0.47) MTORRICTORRPTORMAPKAP1MLST8
SCHEMBL30382424 0.68 KDM4E (0.40) CDK1
SCHEMBL22494311 0.67 MTOR (0.77) PTK6MTORRICTORRPTORMAPKAP1
SCHEMBL4572205 0.66 PIK3CD (0.36) MTORPIK3CASRCABL1HCK
SCHEMBL22494329 0.66 MTOR (0.50) MTORRICTORRPTORMAPKAP1MLST8
SCHEMBL22494331 0.66 MTOR (0.50) MTORRICTORRPTORMAPKAP1MLST8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11731973-B2 Substituted pyrazolo[3,4-d]pyrimidines as mTOR inhibitors GALDERMA RESEARCH & DEVELOPMENT (FR) 2023-08-22 US disclosed
EP-3727389-B1 COMPOUNDS AS MTOR INHIBITORS GALDERMA RES & DEV (FR) 2023-05-03 EP disclosed
US-20200317679-A1 NOVEL MTOR INHIBITOR COMPOUNDS GALDERMA RESEARCH & DEVELOPMENT (FR) 2020-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200317679-A1 NOVEL MTOR INHIBITOR COMPOUNDS MTOR, RICTOR, RPTOR PTK6 679/4885MTOR 1/4885RICTOR 2/4885
US-11731973-B2 Substituted pyrazolo[3,4-d]pyrimidines as mTOR inhibitors MTOR, RICTOR, RPTOR PTK6 603/4885MTOR 1/4885RICTOR 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.